Faes Farma
FAE.MC Small CapHealthcare · Drug Manufacturers - Specialty & Generic
Mis à jour: Aug 2, 2026, 22:14 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Faes Farma en bref
Faes Farma (FAE.MC) is currently trading at 4,56 € with a market capitalization of 1,2 Md €. The trailing P/E ratio stands at 16.89x, with a forward P/E of 12.94x. The 52-week range spans from 4,10 € to 5,44 €; the current price is 16.2% below the yearly high. Year-over-year revenue growth stands at +30.8%. The net profit margin stands at 12.17%.
💰 Dividende
Faes Farma pays an annual dividend of 0,13 € per share, representing a yield of 2.85%. The payout ratio stands at 47.76%.
📊 Avis des analystes
4 analystes évaluent Faes Farma (FAE.MC) au consensus : Acheter. L'objectif de cours moyen est de 5,36 €, soit un potentiel de +17.43% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 4,82 € à 6,00 €.
Faes Farma : la thèse d'investissement en détail
Faes Farma (FAE.MC) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in Spain. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Top-line momentum is unusually strong with revenue expanding 30.8% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 64.39%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Buy with an average price target implying roughly 17.43% upside from current levels — analyst sentiment is firmly constructive.
Valorisation en contexte
With a PEG ratio of 0.91, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.
À surveiller
- The forward P/E of 12.94x is meaningfully below the trailing 16.89x — analysts expect earnings to step up; the next earnings release is the test.
Thèse d'investissement : forces et faiblesses
- Forte croissance du CA de 30.8% sur un an
- Marge brute élevée de 64.39% — signe d'un pouvoir de fixation des prix
- Consensus des analystes : Buy
- Actuellement jugée sous-évaluée
- Rendement du dividende solide de 2.85%
Aucun signal d'alerte significatif dans les indicateurs actuels.
Aperçu technique
The price is in a transition zone relative to the moving averages — no clear signal.
Profil de risque
The data points to relatively defensive market behavior.
Trading Data
💵 Dividend Info
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Faes Farma?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news